A phase II trial to investigate topically applied DUR-928

Trial Profile

A phase II trial to investigate topically applied DUR-928

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Psoriasis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2018 New trial record
    • 01 Mar 2018 According to a DURECT Corporation media release, the company has had pre-IND interactions with the FDA and is completing the last non-clinical study requested by the FDA prior to submitting the IND in the second quarter of 2018. This trial is expected to be initiated in the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top